References
- Vaidya K, Tucker B, Patel S, Ng MKC. Acute Coronary Syndromes (ACS)—Unravelling Biology to Identify New Therapies—The Microcirculation as a Frontier for New Therapies in ACS. Cells. 2021;10(9):2188. doi: 10.3390/cells10092188.
- Scarsini R, Kotronias RA, Della F. Angiography-Derived Index of Microcirculatory Resistance to Define the Risk of Early Discharge in STEMI. Circ Cardiovasc Interv. 2024;17(3). doi: 10.1161/CIRCINTERVENTIONS.123.013556.
- Brainin P, Frestad D, Prescott E. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: A systematic review and meta-analysis. Int J Cardiol. 2018;254:1-9. doi: 10.1016/j.ijcard.2017.10.052.
- Dogheim GM, Amralla MT, Werida RH. Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level. Inflammopharmacology. 2022;30:1617–1622. doi: 10.1007/s10787-022-01028-5.
- Ciobanu L, Popovici I, Ivanov V, Cobet V, Ivanov M, Popovici M. Diagnostic and prognostic value of neopterin and RNA-ase in patients with STEMI and NSTEMI. Eur Heart J. 2020;41(Suppl 2):ehaa946.1681. Available from: https://academic.oup.com/eurheartj/article/41/Supplement_2/ehaa946.1681/6003568.
- Behnoush AH, Khalaji A, Bahiraie P, Alehossein P. Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis. Hypertens Res. 2023;46:2388–2399. doi: 10.1038/s41440-023-01402-y.
- Szarpak T, Pruc M, Swieczkowski D. Diagnostic and Prognostic Value of Endocan in Acute Coronary Syndromes: A Meta-Analysis Comparing STEMI, NSTEMI, and Control Groups. TRC J Med. 2024;2(1):0004. doi: 10.55280/trcjm.2024.2.1.0004.
- Chen J, Jiang L, Yu XH. Endocan: a key player of cardiovascular disease. Front Cardiovasc Med. 2022;8. doi: 10.3389/fcvm.2021.798699.
- Hirooka Y. How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension? Hypertens Res. 2024;47:794–795. doi: 10.1038/s41440-023-01542-1.
- Pakhtusov NN, Iusupova AO, Privalova EV. Endothelial dysfunction and inflammation in patients with non-obstructive coronary arteries. Kardiologiia. 2021;61(1):52-58. doi: 10.18087/cardio.2021.1.n1423.
- Pagonas N, Mueller R, Weiland L, Jaensch M, Westhoff TH, Buschmann IR, Sasco B, Ritter O, Kelesidis TH. Oxidation of HDL in patients with coronary artery disease. Eur Heart J. 2020;41(Suppl 2):ehaa946.1521. Available from: https://academic.oup.com/eurheartj/article/41/Supplement_2/ehaa946.1521/6005868.
- Popovici I, Ivanov V, Popovici I, Ciobanu L, Cobet V, Popovici M. Predictors of 1-year follow-up period MACE in patients with NSTEMI. Eur Heart J. 2024;45(Suppl 1):ehae666.1303. Available from: https://academic. oup.com/eurheartj/article/45/Supplement_1/ehae666.1303/7837553.
- Kindberg K, Broch K, Andersen G, Anstesrtud A, Akkra S, Woxholt S, Tollesen L. Neutrophil Extracellular Traps in ST-Segment Elevation Myocardial Infarction: Reduced by Tocilizumab and Associated With Infarct Size. JACC Adv. 2024;3(9):101193. doi: 10.1016/j.jacadv.2024.101193.
- Tian R, Wang Z, Zhang S, Wang X, Zhang Y, Yuan J, Zhang J. Growth differentiation factor-15 as a biomarker of coronary microvascular dysfunction in ST-segment elevation myocardial infarction. Heliyon. 2024;10(15):e35476. doi: 10.1016/j.heliyon.2024.e35476.
- Sanip Z, Rasool AH, Pahimi N. Elevated inflammation and adhesion molecule hsCRP, GDF-15 and VCAM-1 in angina patients with non-obstructive coronary artery disease. Malays J Med Sci. 2024;31(6):148–159. doi: 10.21315/mjms2024.31.6.12.
- Stoinescu AI, Barbul E, Balanescu SM. Unraveling MINOCA: The hidden impact of inflammation on myocardial infarction without coronary obstruction. Rom J Cardiol. 2025;35(3):175-187. doi: 10.2478/rjc-2025-0016.
- Diau JL, Lange RA. Coronary inflammation and cardiovascular events in patients without obstructive coronary artery disease. Curr Cardiol Rep. 2025;27(1):68. doi: 10.1007/s11886-025-02221-y.
- Bokhari SFH, Umais M, Sattar SM, Mehboob U, Iqbal A. Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis and risk stratification of cardiac diseases. World J Cardiol. 2025;17(7):106561. doi: 10.4330/wjc.v17.i7.106561.